DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights. First Quarter 2023 Financial Highlights Cash position Cash, cash equivalents…


Previous articleCOMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
Next articleClearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder